{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T12:36:22Z","timestamp":1765370182193,"version":"3.40.5"},"reference-count":18,"publisher":"Walter de Gruyter GmbH","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2022-1213_abs_001\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Amphotericin B (AmB) is the gold standard for treating invasive fungal infections. New liposomal-containing AmB formulations have been developed to improve efficacy and tolerability. Serum\/plasma C-reactive protein (CRP) values are widely used for monitoring infections and inflammation. CRP shows a high affinity to phosphocholine and it aggregates structures bearing this ligand, e.g. phosphocholine-containing liposomes. Therefore, we studied the interaction between CRP and phosphocholine-containing liposomal AmB preparations <jats:italic>in\u00a0vivo<\/jats:italic> and <jats:italic>in\u00a0vitro<\/jats:italic>.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2022-1213_abs_002\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>CRP was prepared by affinity chromatography. Liposomal AmB (L-AmB, AmBisome<jats:sup>\u00ae<\/jats:sup>) was spiked (final concentrations of L-AmB: 150\u00a0mg\/L) to CRP-containing serum (final CRP concentration: 300\u00a0mg\/L). Following the addition of L-AmB, complex formation was monitored turbidimetrically. The size of CRP-L-AmB complexes was assessed using gel filtration. CRP was monitored in patients receiving either L-Amb or AmB lipid complex (ABLC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2022-1213_abs_003\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Following addition of L-AmB to CRP-containing plasma, turbidimetry showed an increase in absorbance. These results were confirmed by gel permeation chromatography. Similarly, <jats:italic>in\u00a0vivo<\/jats:italic> effects were observed following intravenous administration of AmBisome<jats:sup>\u00ae<\/jats:sup>: a decline in CRP values was observed. In patients receiving L-Amb, decline of CRP concentration was faster than in patients receiving ABLC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2022-1213_abs_004\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>\n                     <jats:italic>In vitro<\/jats:italic> experiments are suggestive of a complexation between CRP and liposomes in plasma. Interpretation of CRP values following administration of AmBisome<jats:sup>\u00ae<\/jats:sup> might be impaired due to this complexation. <jats:italic>In vivo<\/jats:italic> formation of complexes between liposomes and CRP might contribute, or even lead, to intravascular microembolisation. Similar effects have been described following the administration of Intralipid<jats:sup>\u00ae<\/jats:sup> and other phosphocholine-containing liposomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2022-1213","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T10:20:37Z","timestamp":1674555637000},"page":"1065-1068","source":"Crossref","is-referenced-by-count":1,"title":["C-reactive protein interacts with amphotericin B liposomes and its potential clinical consequences"],"prefix":"10.1515","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5702-6792","authenticated-orcid":false,"given":"Joris R.","family":"Delanghe","sequence":"first","affiliation":[{"name":"Department of Diagnostic Sciences , Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Himpe","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Sciences , Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerina","family":"Boelens","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Sciences , Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Benoit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Ghent University Hospital , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram","family":"Gadeyne","sequence":"additional","affiliation":[{"name":"Department of Development of Healthcare Applications , Ghent University Hospital , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijn M.","family":"Speeckaert","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine , Ghent University Hospital , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick","family":"Verbeke","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Sciences , Ghent University , Ghent , Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2023,1,25]]},"reference":[{"key":"2023042108131339969_j_cclm-2022-1213_ref_001","doi-asserted-by":"crossref","unstructured":"Adler-Moore, JP, Proffitt, RT. Amphotericin B lipid preparations: what are the differences? Clin Microbiol Infect 2008;14:5\u201336. https:\/\/doi.org\/10.1111\/j.1469-0691.2008.01979.x.","DOI":"10.1111\/j.1469-0691.2008.01979.x"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_002","doi-asserted-by":"crossref","unstructured":"Hamill, RJ, Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs 2013;73:919\u201334. https:\/\/doi.org\/10.1007\/s40265-013-0069-4.","DOI":"10.1007\/s40265-013-0069-4"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_003","doi-asserted-by":"crossref","unstructured":"Adler-moore, JP, Proffitt, RT. Development, characterization, efficacy and mode of action of AmBisome, A unilamellar liposomal formulation of amphotericin B. J Liposome Res 1993;3:429\u201350. https:\/\/doi.org\/10.3109\/08982109309150729.","DOI":"10.3109\/08982109309150729"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_004","doi-asserted-by":"crossref","unstructured":"Fujii, G, Chang, JE, Coley, T, Steere, B. The formation of amphotericin B ion channels in lipid bilayers. Biochemistry 1997;36:4959\u201368. https:\/\/doi.org\/10.1021\/bi962894z.","DOI":"10.1021\/bi962894z"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_005","doi-asserted-by":"crossref","unstructured":"Janoff, AS, Boni, LT, Popescu, MC, Minchey, SR, Cullis, PR, Madden, TD, et al.. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988;85:6122\u20136. https:\/\/doi.org\/10.1073\/pnas.85.16.6122.","DOI":"10.1073\/pnas.85.16.6122"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_006","doi-asserted-by":"crossref","unstructured":"Guo, LSS, Fielding, RM, Lasic, DD, Hamilton, RL, Mufson, D. Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. Int J Pharm 1991;75:45\u201354. https:\/\/doi.org\/10.1016\/0378-5173(91)90249-N.","DOI":"10.1016\/0378-5173(91)90249-N"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_007","doi-asserted-by":"crossref","unstructured":"Hulman, G. Fat macroglobule formation from chylomicrons and non-traumatic fat embolism. Clin Chim Acta 1988;177:173\u20138. https:\/\/doi.org\/10.1016\/0009-8981(88)90139-8.","DOI":"10.1016\/0009-8981(88)90139-8"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_008","doi-asserted-by":"crossref","unstructured":"Zagara, G, Scaravilli, P, Locati, L, Seveso, M. C-reactive protein and serum agglutination in\u00a0vivo of intravenous fat emulsions. Lancet 1989;1:733. https:\/\/doi.org\/10.1016\/s0140-6736(89)92254-x.","DOI":"10.1016\/S0140-6736(89)92254-X"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_009","unstructured":"Rowe, IR, Soutar, AK, Pepys, MB. Agglutination of intravenous lipid emulsion (\u2018Intralipid\u2019) and plasma lipoproteins by C-reactive protein. Clin Exp Immunol 1986;66:241\u20137."},{"key":"2023042108131339969_j_cclm-2022-1213_ref_010","unstructured":"Tuckwell, KR. MIMS Annual., Sydney, Australia, n.d. Intralipid. Pharmacia and UpJohn product information. MIMS Annual 1997;19:1110\u20131."},{"key":"2023042108131339969_j_cclm-2022-1213_ref_011","doi-asserted-by":"crossref","unstructured":"Hulman, G, Pearson, HJ, Fraser, I, Bell, PR. Agglutination of intralipid by serum. Lancet 1983;1:985\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(83)92105-0.","DOI":"10.1016\/S0140-6736(83)92105-0"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_012","doi-asserted-by":"crossref","unstructured":"Tugirimana, P, Speeckaert, MM, Fiers, T, De Buyzere, ML, Kint, J, Benoit, D, et al.. Agglutination of intravenously administered phosphatidylcholine-containing lipid emulsions with serum C-reactive protein. Nutr Clin Pract 2013;28:253\u20139. https:\/\/doi.org\/10.1177\/0884533612474040.","DOI":"10.1177\/0884533612474040"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_013","doi-asserted-by":"crossref","unstructured":"Volanakis, JE, Clements, WL, Schrohenloher, RE. C-reactive protein: purification by affinity chromatography and physicochemical characterization. J Immunol Methods 1978;23:285\u201395. https:\/\/doi.org\/10.1016\/0022-1759(78)90203-X.","DOI":"10.1016\/0022-1759(78)90203-X"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_014","doi-asserted-by":"crossref","unstructured":"Tugirimana, PL, Holderbeke, AL, Kint, JA, Delanghe, JR. A new turbidimetric method for assaying serum C-reactive protein based on phosphocholine interaction. Clin Chem Lab Med 2009;47:1417\u201322. https:\/\/doi.org\/10.1515\/CCLM.2009.312.","DOI":"10.1515\/CCLM.2009.312"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_015","doi-asserted-by":"crossref","unstructured":"Pepys, MB, Hirschfield, GM. C-reactive protein: a critical update. J Clin Invest 2003;111:1805\u201312. https:\/\/doi.org\/10.1172\/JCI18921.","DOI":"10.1172\/JCI200318921"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_016","doi-asserted-by":"crossref","unstructured":"Bellmann, R. Pharmacodynamics and pharmacokinetics of antifungals for treatment of invasive aspergillosis, Curr Pharmaceut Des 2013;19:3629\u201347. https:\/\/doi.org\/10.2174\/13816128113199990332.","DOI":"10.2174\/13816128113199990332"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_017","doi-asserted-by":"crossref","unstructured":"Christofilopoulou, S, Charvalos, E, Petrikkos, G. Could procalcitonin be a predictive biological marker in systemic fungal infections? Study of 14 cases. Eur J Intern Med 2002;13:493\u20135. https:\/\/doi.org\/10.1016\/s0953-6205(02)00160-7.","DOI":"10.1016\/S0953-6205(02)00160-7"},{"key":"2023042108131339969_j_cclm-2022-1213_ref_018","doi-asserted-by":"crossref","unstructured":"Tolentino, LF, Tsai, SF, Witt, MD, French, SW. Fatal fat embolism following amphotericin B lipid complex injection. Exp Mol Pathol 2004;77:246\u20138. https:\/\/doi.org\/10.1016\/j.yexmp.2004.07.001.","DOI":"10.1016\/j.yexmp.2004.07.001"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1213\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1213\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T08:26:23Z","timestamp":1682065583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2022-1213\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,25]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,26]]},"published-print":{"date-parts":[[2023,5,25]]}},"alternative-id":["10.1515\/cclm-2022-1213"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2022-1213","relation":{},"ISSN":["1434-6621","1437-4331"],"issn-type":[{"type":"print","value":"1434-6621"},{"type":"electronic","value":"1437-4331"}],"subject":[],"published":{"date-parts":[[2023,1,25]]}}}